MedTrace Logo

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

NCT01309399 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-11-23

No results posted yet for this study

Summary

Teriparatide is a potent osteoporosis medication that helps prevent fractures, however, the investigators know little about its effect on the hip. The investigators will evaluate hip bone samples from patients treated with teriparatide before undergoing hip replacement. The information will help us understand how teriparatide might help reduce hip fracture risk.

Conditions

Interventions

DRUG

Teriparatide

six weeks of teriparatide

OTHER

placebo

placebo

Sponsors & Collaborators

  • Hospital for Special Surgery, New York

    collaborator OTHER

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • Health Research, Inc.

    lead OTHER

Principal Investigators

  • Felicia Cosman, M.D. · Helen Hayes Hospital

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2014-11-30
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01309399 on ClinicalTrials.gov